Jefferies Financial Group Inc. Lowers Holdings in Hologic, Inc. (NASDAQ:HOLX)

Key Points

• Jefferies Financial Group Inc. has reduced its stake in Hologic, Inc. by 42.2% during the first quarter, now holding 56,000 shares valued at approximately $3.46 million.
• Hologic reported a quarterly earnings per share (EPS) of $1.08, exceeding analyst expectations, with revenues of $1.02 billion, marking a 1.2% increase year-over-year.
• Most of Hologic’s shares, about 94.73%, are currently held by institutional investors and hedge funds, reflecting strong institutional interest in the company.

Jefferies Financial Group Inc. trimmed its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 42.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 56,000 shares of the medical equipment provider's stock after selling 40,849 shares during the period. Jefferies Financial Group Inc.'s holdings in Hologic were worth $3,459,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Farther Finance Advisors LLC grew its position in Hologic by 22.3% during the first quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider's stock valued at $113,000 after acquiring an additional 335 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Hologic by 116.6% in the first quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider's stock worth $594,000 after purchasing an additional 5,172 shares during the last quarter. Brevan Howard Capital Management LP grew its holdings in shares of Hologic by 85.5% in the fourth quarter. Brevan Howard Capital Management LP now owns 19,436 shares of the medical equipment provider's stock worth $1,401,000 after purchasing an additional 8,960 shares during the last quarter. Cambridge Investment Research Advisors Inc. grew its holdings in shares of Hologic by 1.7% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 32,056 shares of the medical equipment provider's stock worth $1,980,000 after purchasing an additional 528 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky grew its holdings in shares of Hologic by 4.5% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 17,945 shares of the medical equipment provider's stock worth $1,108,000 after purchasing an additional 767 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Stock Performance

Shares of Hologic stock traded down $0.25 during trading hours on Tuesday, reaching $67.67. 62,556 shares of the stock traded hands, compared to its average volume of 2,852,425. The company has a 50 day moving average price of $64.69 and a 200 day moving average price of $62.71. The firm has a market capitalization of $15.05 billion, a price-to-earnings ratio of 28.01, a P/E/G ratio of 2.43 and a beta of 0.49. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.67. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%. The firm had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. During the same period in the previous year, the firm earned $1.06 EPS. The business's quarterly revenue was up 1.2% on a year-over-year basis. On average, equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Hologic news, Director Martin D. Madaus purchased 5,445 shares of the stock in a transaction that occurred on Wednesday, May 7th. The shares were bought at an average cost of $55.24 per share, with a total value of $300,781.80. Following the acquisition, the director owned 5,445 shares in the company, valued at approximately $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.88% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently commented on HOLX shares. Morgan Stanley raised their price target on Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 31st. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and raised their price target for the stock from $60.00 to $80.00 in a research note on Wednesday, July 9th. Stephens dropped their price target on Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research note on Tuesday, May 13th. Mizuho set a $75.00 price target on Hologic in a research note on Thursday. Finally, Wall Street Zen lowered Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $76.42.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.